Cas:91955-44-1 1-[4-(4-Nitrophenoxy)phenyl]methanamine manufacturer & supplier

Chemical Name:1-[4-(4-Nitrophenoxy)phenyl]methanamine

CAS.NO:91955-44-1

Synonyms:Benzenemethanamine, 4-(4-nitrophenoxy)-;1-[4-(4-Nitrophenoxy)phenyl]methanamine

Molecular Formula:C₁₃H₁₂N₂O₃

Molecular Weight:244.246

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:383.7±27.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.623

PSA:81.07000

Exact Mass:244.084793

LogP:2.80

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzenemethanamine, 4-(4-nitrophenoxy)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[4-(4-Nitrophenoxy)phenyl]methanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[4-(4-Nitrophenoxy)phenyl]methanamine Use and application,1-[4-(4-Nitrophenoxy)phenyl]methanamine technical grade,usp/ep/jp grade.

Related News: The site, near Dehradun in the Himalayan foothills, will have a capacity to produce 1 billion units annually, delivering vials filled with liquid and powder, lyophilized vials, dental cartridges and prefilled syringes. [3-(16-methylheptadecanoyloxy)-2,2-bis(16-methylheptadecanoyloxymethyl)propyl] 16-methylheptadecanoate manufacturers The site, near Dehradun in the Himalayan foothills, will have a capacity to produce 1 billion units annually, delivering vials filled with liquid and powder, lyophilized vials, dental cartridges and prefilled syringes. α,β-METHYLENEADENOSINE 5′-DIPHOSPHATE SODIUM SALT suppliers Italian medical packaging firm Stevanato Group went public on the Big Board on July 16, raising $672 million and helping push up the fortune of the billionaire Stevanato family behind the company. Benzyl 3-oxopyrrolidine-1-carboxylate vendor & factory The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment.,In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion.